Connect Biopharma Holdings (CNTB) Cash from Operations (2024 - 2026)

Connect Biopharma Holdings has disclosed Cash from Operations across 3 years of filings, most recently posting -$15.9 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 26.46% year-over-year to -$15.9 million; the TTM figure through Jun 2026 stood at -$60.6 million (down 59.95% YoY), while the FY2025 annual figure was -$51.2 million, down 116.86% from the prior year.
• Cash from Operations came in at -$15.9 million for Q2 2026 at Connect Biopharma Holdings, up from -$16.0 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$591000.0 in Q1 2024 to a low of -$17.4 million in Q3 2025.
• Average Cash from Operations over 3 years is -$10.7 million, with a median of -$11.9 million recorded in 2025.
• Year-over-year, Cash from Operations slumped 1585.11% in 2025 and fell 26.46% in 2026.
• Over 3 years, Cash from Operations stood at -$2.3 million in 2024, then tumbled by 385.12% to -$11.2 million in 2025, then plunged by 41.53% to -$15.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$15.9 million in Q2 2026, -$16.0 million in Q1 2026, and -$11.2 million in Q4 2025.